Nature Reviews Cancer 3, 666-675 (September 2003) | doi:10.1038/nrc1167

Adoptive-cell-transfer therapy for the treatment of patients with cancer

Mark E. Dudley1 & Steven A. Rosenberg1  About the authors


Adoptive immunotherapy — the isolation of antigen-specific cells, their ex vivo expansion and activation, and subsequent autologous administration — is a promising approach to inducing antitumour immune responses. The molecular identification of tumour antigens and the ability to monitor the persistence and transport of transferred cells has provided new insights into the mechanisms of tumour immunotherapy. Recent studies have shown the effectiveness of cell-transfer therapies for the treatment of patients with selected metastatic cancers. These studies provide a blueprint for the wider application of adoptive-cell-transfer therapy, and emphasize the requirement for in vivo persistence of the cells for therapeutic efficacy.

Author affiliations

  1. Surgery Branch, National Cancer Institute, Building 10, Room 2B-34, 10 Center Drive, Bethesda, Maryland 20892-1502, USA.

Correspondence to: Mark E. Dudley1 Email:

These links to content published by NPG are automatically generated

Tumour Immunology
Nature Encyclopaedia of Life Sciences
Tumours: Immunotherapy
Nature Encyclopaedia of Life Sciences
See all 3 matches for Reference

Trafficking of 'immune' CD4+/CD8+ T-lymphocytes into the RENCA tumour microcirculation in vivo in mice
British Journal of Cancer Research Article (01 Oct 2000)
Restored T-cell activation mechanisms in human tumour-infiltrating lymphocytes from melanomas and colorectal carcinomas after exposure to interleukin-2
British Journal of Cancer Original Article (27 Jan 2003)
See all 5 matches for Research